- Home
- JANX vs CNXC Comparison
JANX vs CNXC Comparison
Compare JANX & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- CNXC
- Stock Information
- Founded
- JANX 2017
- CNXC 1991
- Country
- JANX United States
- CNXC United States
- Employees
- JANX N/A
- CNXC N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- CNXC Computer Software: Prepackaged Software
- Sector
- JANX Health Care
- CNXC Technology
- Exchange
- JANX Nasdaq
- CNXC Nasdaq
- Market Cap
- JANX 1.4B
- CNXC 3.6B
- IPO Year
- JANX 2021
- CNXC N/A
- Fundamental
- Price
- JANX $24.06
- CNXC $56.78
- Analyst Decision
- JANX Strong Buy
- CNXC Buy
- Analyst Count
- JANX 7
- CNXC 4
- Target Price
- JANX $94.29
- CNXC $68.75
- AVG Volume (30 Days)
- JANX 659.3K
- CNXC 838.9K
- Earning Date
- JANX 08-06-2025
- CNXC 06-26-2025
- Dividend Yield
- JANX N/A
- CNXC 2.35%
- EPS Growth
- JANX N/A
- CNXC N/A
- EPS
- JANX N/A
- CNXC 3.65
- Revenue
- JANX $9,336,000.00
- CNXC $9,625,029,000.00
- Revenue This Year
- JANX N/A
- CNXC $2.01
- Revenue Next Year
- JANX $1,470.82
- CNXC $2.82
- P/E Ratio
- JANX N/A
- CNXC $15.53
- Revenue Growth
- JANX 28.12
- CNXC 11.31
- 52 Week Low
- JANX $22.48
- CNXC $36.28
- 52 Week High
- JANX $71.71
- CNXC $77.00
- Technical
- Relative Strength Index (RSI)
- JANX 48.08
- CNXC 55.77
- Support Level
- JANX $22.74
- CNXC $50.80
- Resistance Level
- JANX $24.73
- CNXC $57.00
- Average True Range (ATR)
- JANX 1.26
- CNXC 2.60
- MACD
- JANX 0.09
- CNXC 0.05
- Stochastic Oscillator
- JANX 47.35
- CNXC 85.68
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CNXC Concentrix Corporation
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.